Collection of Circulating Biomarkers in Pancreatic Cancer

Pancreas Cancer Clinical Trial

Official title:

Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05743049
• Other study ID #: UPCC 20222
• Secondary ID: 852628
• Status: Recruiting
• Start date: February 27, 2023
• Est. completion date: February 15, 2024

Study information

• Verified date: October 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: Liudmila Mazaleuskaya, PhD
• Phone: 267-455-9141
• Email: mazali[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: February 15, 2024
• Est. primary completion date: January 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma

• The subject must be a patient of the University of Pennsylvania

• The subject must be able to provide informed consent

• The subject must be 18 years of age or older

Exclusion Criteria:

. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Related Conditions & MeSH terms

• Pancreas Cancer
• Pancreatic Neoplasms

Intervention

Other:
• Obtaining blood for analysis of various circulating biomarkers
4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

Locations

Country	Name	City	State
United States	Abramson Cancer Center at University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.		Through study completion, an average of 1 year
Secondary	To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.		Through study completion, an average of 1 year
Secondary	To integrate the data and specimens to permit the most informative clinical-biologic research platform.		Through study completion, an average of 1 year